Skip to main content
OpenTrials
Completed

NCT Number: NCT02097654

Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons

Primary Objective: To quantify the benefits of the SENATOR decision support software on the reduction of ADR rates in older hospitalized patients. Secondary Objectives: To evaluate the effect of SENATOR with regard to use of appropriate non-pharmacological therapies in subjects with one core geriatric syndrome.

Tertiary Objectives: to examine the association of SENATOR use with subject survival, morbidity and health related quality of life.

Health Economic Objective: To examine the potential health economic consequences of using SENATOR.

There are two study phases:

Phase I: Prospective multinational, multicentre observational study to estimate the baseline adjudicated medical and surgical ADR rates by clinical subspeciality in 6 international sites.

Phase II: Prospective multinational, multicentre, block randomized, two parallel arm, open label, controlled trial, with blinded outcome ascertainment, of the efficacy of SENATOR software in reducing ADRs in older hospitalized subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University College Cork

Cork, Munster, 2, Ireland

About this study

Phase I is designed to test the electronic case report form (eCRF) and the ADR ascertainment method in the six clinical sites in advance of Phase II (randomization phase).

In Phase I, we recruited 644 older multi-morbid patients from the 6 clinical sites. After obtaining written informed consent, patients' demographic, clinical and medication details were entered to the eCRF. In the event of one a 12 item Trigger List of adverse clinical events occurring, the eCRF automatically generated a Trigger List assessment proforma. The 12 items in the Trigger List included:

  • New onset falls
  • New onset unsteady gait
  • Acute kidney injury
  • Symptomatic orthostatic hypotension
  • Serum electrolyte disturbance
  • Symptomatic bradycardia
  • New onset major constipation
  • Acute bleeding
  • Acute dyspepsia/nausea/vomiting
  • Acute diarrhea
  • Delirium
  • Symptomatic hypoglycemia

In addition, we have included 'Unspecified adverse event' in order to capture the wide range of well recognized ADRs associated with various medications. For example, the rapid onset of a generalized maculopapular rash in a patient with penicillin hypersensitivity would be identified as an ADR under the 'Unspecified adverse event' category.

ADR adjudication in Phase I was blinded and no ADR adjudications were undertaken by the site principal investigator (PI). ADRs were defined as 'definite', probable', 'possible', 'unlikely' or 'indeterminate' according to WHO-UMC ADR causality critria. ADR severity was defined according to a modified Hartwig ADR severity scale ranging from Level 1 (trivial) to Level 7 (fatal).

Consensus on ADR causality was achieved through a potential endpoint adjudication committee (PEPAC), whose members were the 6 clinical site PI's. A matrix for achieving consensus was devised, such that there was a final decision on the causality of all potential ADRs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of informed consent by the patient or legal guardian/next-of-kin
  • Age ≥ 65 years
  • Arrival to hospital within previous 72 hours
  • Admitted as a general medical or surgical on call patient
  • Anticipated in-hospital stay of > 48 hours,
  • ≥ 3 active (requiring current medication) chronic medical disorders

Exclusion criteria

  • Admitted under:
  • Geriatric Medicine
  • Clinical Pharmacology
  • Palliative Medicine
  • Clinical Oncology
  • Hematology
  • Intention of primary team at the time of subject admission to seek a Geriatric Medicine, Clinical Pharmacology or Palliative Medicine in-patient consultation
  • Life expectancy in the opinion of the admitting clinician of < 3 months
  • Admission directly to an intensive care unit,
  • Admission with primary acute psychiatric illness (excluding delirium)
  • Admission with non-accidental overdose/self-harm
  • Anticipated immediate transfer to alternative non-participating clinical service/hospital
  • Clinical diagnosis of acute Liver failure
  • estimated Glomerular Filtration Rate <10 ml/min per 1.73 m2
  • Solid organ transplant recipients
  • Patients with malignancy receiving systemic chemotherapy
  • Hospitalized for elective procedure
  • Patient was more than 24 hours in the Emergency Department under the care of a different team to that which finally is in charge of them
  • Patients who are actively participating in another clinical trial

Treatment and study plan

SENATOR software generated pharmacotherapy advice report.

Other

Primary outcomes

  1. Incident adverse drug reactions (ADRs). at least one likely or certain, non-trivial hospital acquired ADR.

    Time frame: Day 14 of hospital stay or discharge, which ever comes first

    Subjects adjudicated by the Potential Endpoint Committee as having experienced one or more probable or certain adverse drug reactions (ADRs).

Sponsors and collaborators

Lead sponsor

University College Cork

Other

Collaborators

  • ARTTIC International Management Services
  • Clanwilliam Health
  • Clininfo S.A.
  • Hospital Universitario Ramon y Cajal
  • Istituto Nazionale di Ricovero e Cura per Anziani
  • Landspitali University Hospital
  • NHS Grampian
  • University Ghent
  • University of East Anglia

Registry information

Official study title

A Prospective, Multinational, Randomized, Open Label Parallel Arm Trial With Blinded Outcome Adjudication Quantifying the Efficacy of SENATOR in Reducing Adverse Drug Reactions in Older Hospitalized Subjects

Acronym: SENATOR

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
Mar 27, 2014
Registry last updated
Jan 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.